Clinical trial
Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2
NCT03666546 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2
- Lead sponsor
- Fresenius Kabi
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 26, 2018
- Completion date
- March 8, 2019
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.